TREM2 — Triggering Receptor Expressed on Myeloid Cells 2

Migration, Crosslink

📖

TREM2 — Triggering Receptor Expressed on Myeloid Cells 2

active

wiki page Created: 2026-04-02T07:19:32 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-trem2

📖 Wiki Page

gene1603 wordssynced 2026-04-02

TREM2 — Triggering Receptor Expressed on Myeloid Cells 2

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TREM2 — Triggering Receptor Expressed on Myeloid Cells 2</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>TREM2</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Triggering Receptor Expressed on Myeloid Cells 2</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>6p21.1</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/54209" target="_blank">54209</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000095970" target="_blank">ENSG00000095970</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/605086" target="_blank">605086</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9NZC2" target="_blank">Q9NZC2</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Frontotemporal Dementia](/diseases/frontotemporal-dementia), [Nasu-Hakola Disease](/diseases/nasu-hakola-disease)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Microglia, Cerebral cortex, Hippocampus</td>
</tr>
<tr>
<th class="infobox-subheader" colspan="2">Key Mutations</th>
</tr>
<tr>
<td colspan="2" style="font-size:0.85em">R47H, R62H, D87N, T66M, Y38C</td>
</tr>
<tr>
<td class

...

TREM2 — Triggering Receptor Expressed on Myeloid Cells 2

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TREM2 — Triggering Receptor Expressed on Myeloid Cells 2</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>TREM2</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Triggering Receptor Expressed on Myeloid Cells 2</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>6p21.1</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/54209" target="_blank">54209</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000095970" target="_blank">ENSG00000095970</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/605086" target="_blank">605086</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9NZC2" target="_blank">Q9NZC2</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Frontotemporal Dementia](/diseases/frontotemporal-dementia), [Nasu-Hakola Disease](/diseases/nasu-hakola-disease)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Microglia, Cerebral cortex, Hippocampus</td>
</tr>
<tr>
<th class="infobox-subheader" colspan="2">Key Mutations</th>
</tr>
<tr>
<td colspan="2" style="font-size:0.85em">R47H, R62H, D87N, T66M, Y38C</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als-therapeutic-landscape-—-programs-by-phase-and-modality" style="color:#ef9a9a">ALS Therapeutic Landscape — Programs by Phase and Modality</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer-disease" style="color:#ef9a9a">ALZHEIMER DISEASE</a>, <a href="/wiki/alzheimer's" style="color:#ef9a9a">ALZHEIMER'S</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-seaad-51323624" style="color:#ce93d8" title="Score: 0.73">Cell-Type Specific TREM2 Upregulation in...</a><br><a href="/hypothesis/h-180807e5" style="color:#ce93d8" title="Score: 0.70">APOE-TREM2 Interaction Modulation...</a><br><a href="/hypothesis/h-3460f820" style="color:#ce93d8" title="Score: 0.58">TREM2-Mediated Selective Aggregate Clear...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1914 edges</a></td>
</tr>
</table>

Overview

TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a gene located on chromosome 6p21.1 that encodes a critical receptor protein expressed primarily on microglia in the central nervous system[@jonsson2013]. Discovered as a major risk factor for Alzheimer's disease, TREM2 has emerged as a central regulator of microglial function, amyloid clearance, and neuroinflammation[@guerreiro2013].

> Key takeaway: TREM2 is a microglial receptor that when mutated (particularly R47H) significantly increases Alzheimer's disease risk by impairing microglial phagocytosis and amyloid clearance.

Gene Structure and Expression

Genomic Organization

The TREM2 gene spans approximately 7.5 kb on chromosome 6p21.1 within the major histocompatibility complex (MHC) class III region. The gene consists of 5 exons encoding a type I transmembrane receptor protein. TREM2 is part of a gene family that includes TREM1, TREM3 (pseudogene), and TREML1-4[@kleinberger2014].

Brain Expression Pattern

TREM2 is predominantly expressed in:

Microglia: The highest expression levels are found in brain microglia, particularly in regions affected by neurodegenerative processes
Cerebral cortex: Layer-specific expression with higher levels in cortical layers associated with sensory processing
Hippocampus: Strong expression in the dentate gyrus and CA regions, areas critical for memory and vulnerable in AD[@wang2015]
Substantia nigra: Moderate expression in dopaminergic regions relevant to Parkinson's disease

Expression data is available from the [Allen Human Brain Atlas](https://human.brain-map.org/microarray/search/show?search_term=TREM2) and single-cell transcriptomic databases showing microglial-specific expression.

Allen Brain Atlas Data

Gene Expression

TREM2 shows highly specific expression patterns in the brain:

Microglia - Highest expression levels of any brain cell type
Cerebral cortex - Layer-specific expression in cortical microglia
Hippocampus - High in dentate gyrus and CA regions
Substantia nigra - Moderate expression in microglial populations

Single-Cell Expression

Single-cell RNA-seq data from the Allen Brain Atlas Cell Types dataset shows:

Microglia - Exclusive expression (highest among all cell types)
Macrophages - High expression in border-associated populations
Other cell types - Minimal to absent expression

Brain Region Expression Levels

| Region | Expression Level | Data Source |
|--------|-----------------|--------------|
| Cortex | High (Microglial) | Human MTG |
| Hippocampus | High (Microglial) | Mouse Brain |
| Substantia nigra | Medium | Mouse Brain |
| Cerebellum | Low | Mouse Brain |

External Resources

[Allen Human Brain Atlas - TREM2](https://human.brain-map.org/microarray/search/show?search_term=TREM2)
[Allen Cell Type Atlas - TREM2](https://celltypes.brain-map.org/)
[Allen Mouse Brain Atlas - TREM2](https://mouse.brain-map.org/)

Transcriptional Regulation

TREM2 expression is regulated by:

CSF1R signaling: Macrophage colony-stimulating factor (M-CSF) and GM-CSF upregulate TREM2 expression
TGF-β: Transforming growth factor beta enhances microglial TREM2 expression
Aβ exposure: Amyloid-beta oligomers induce TREM2 upregulation as a compensatory response
Inflammatory cytokines: IFN-γ and TNF-α can modulate TREM2 expression levels

Function

TREM2 Signaling Pathway

TREM2 functions as an activating receptor on microglia that triggers intracellular signaling cascades through its association with the adaptor protein DAP12 (TYROBP). Upon ligand binding[@zhao2018]:

Mermaid diagram (expand to render)

Key Functions

Phagocytosis: TREM2 is essential for microglial phagocytosis of[@gratuze2018]:

Amyloid-beta plaques
Apoptotic neurons
Synaptic debris
Lipids and cellular waste

Microglial Survival: TREM2 signaling promotes microglial survival through AKT and mTOR pathways

Metabolic Reprogramming: TREM2 activation induces glycolytic shift necessary for active phagocytosis

Cytokine Production: TREM2 signaling modulates production of anti-inflammatory cytokines (IL-10, TGF-β) while limiting pro-inflammatory responses

Synaptic Pruning: During development and in disease states, TREM2 mediates appropriate synaptic elimination[@painter2015]

TREM2 Ligands

TREM2 recognizes several key ligands:

Amyloid-beta: Direct binding of Aβ oligomers to TREM2
Lipids: Phosphatidylserine, oxidized lipids, HDL particles
ApoE: Lipidated apolipoproteins serve as bridging molecules
TREM2 ligand (TREM2-L): Identified as an endogenous ligand

Protein Interactions

TREM2 interacts with several key proteins:

| Partner | Interaction Type | Functional Consequence |
|---------|-----------------|----------------------|
| DAP12 (TYROBP) | Direct binding | ITAM-mediated signal transduction |
| DAP10 | Alternative adaptor | PI3K-mediated signaling |
| SYK | Kinase substrate | Signal propagation |
| PI3K | Phosphorylation | AKT pathway activation |
| PLCγ | Substrate | Calcium signaling |
| APOE | Lipid ligand | Aβ binding and clearance |

Disease Associations

Alzheimer's Disease

TREM2 variants represent one of the strongest genetic risk factors for late-onset Alzheimer's disease (LOAD) after APOE. The R47H variant increases AD risk by approximately 3-fold, similar to the effect of one APOE4 allele[@ulrich2017].

Mechanisms linking TREM2 to AD:

Impaired Aβ clearance: TREM2 mutations reduce microglial phagocytosis of amyloid-beta
Plaque pathology: TREM2-deficient mice show increased amyloid deposition
Neuroinflammation: Altered cytokine profiles and chronic inflammation
Synaptic loss: Impaired synaptic pruning mechanisms

Frontotemporal Dementia

TREM2 variants are associated with increased risk for frontotemporal dementia, particularly in cases with:

TDP-43 pathology
Earlier age of onset
Behavioral variant FTD phenotype

Nasu-Hakola Disease

Homozygous loss-of-function mutations in TREM2 cause Nasu-Hakola disease (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy - PLOSL), characterized by:

Early-onset dementia
Bone cysts
Progressive leukoencephalopathy

This demonstrates the critical role of TREM2 in neuronal function[@kleinberger2014].

Parkinson's Disease

TREM2 variants may modify risk in Parkinson's disease, though evidence is less robust than for AD. Studies suggest TREM2 may be involved in:

Alpha-synuclein clearance
Microglial response to dopaminergic neuron loss

Amyotrophic Lateral Sclerosis

TREM2 expression changes in motor neurons and may play a role in:

Microglial activation
Neuroinflammation in ALS

Multiple Sclerosis

TREM2 is involved in microglial response to demyelination and may play a protective role in MS progression.

Key Disease-Associated Mutations

| Variant | Risk | Effect | Population Frequency |
|---------|------|--------|---------------------|
| R47H | ~3x AD risk | Loss of ligand binding | ~0.5% European |
| R62H | ~1.5x AD risk | Partial loss of function | ~1% European |
| D87N | ~2x AD risk | Reduced signaling | Rare |
| T66M | Pathogenic (NHD) | Complete loss of function | Very rare |
| Y38C | Pathogenic (NHD) | Misfolding | Very rare |

The R47H variant specifically impairs binding to amyloid-beta and lipid ligands, explaining its strong effect on AD risk[@elahi2020].

Therapeutic Implications

TREM2-Targeting Therapies

Given TREM2's critical role in AD pathogenesis, several therapeutic approaches are being developed[@xiang2024]:

TREM2 Agonists: Monoclonal antibodies that activate TREM2 signaling to enhance microglial function

Small Molecule Agonists: Blood-brain barrier permeable compounds that enhance TREM2 activity

Gene Therapy: Viral vector delivery of functional TREM2

Protein Replacement: Delivery of soluble TREM2 (sTREM2) to restore function

Clinical Trials

Several TREM2-targeted therapies are in various stages of development:

Anti-TREM2 antibodies: Phase 1/2 trials for AD
Small molecule TREM2 activators: Preclinical development
Gene therapy approaches: Early research phase

Biomarker Potential

Soluble TREM2 (sTREM2) in cerebrospinal fluid reflects microglial activity and[@schneck2021]:

Increases in early AD
Correlates with disease progression
May serve as a biomarker for microglial activation

Research Challenges

Achieving adequate brain penetration
Balancing beneficial versus harmful inflammation
Timing of intervention (early vs. late disease)
Understanding TREM2's role in normal brain function

References

[Jonsson et al., Variant in TREM2 associated with Alzheimer's disease (2013)](https://doi.org/10.1056/NEJMoa1211851)

[Guerreiro et al., TREM2 variants in Alzheimer's disease (2013)](https://doi.org/10.1056/NEJMoa1211851)

[Wang et al., TREM2 deficiency eliminates the neuroprotective function of resolving microglia (2015)](https://doi.org/10.1038/nn.4057)

[Ulrich et al., A decade of TREM2 in Alzheimer's disease (2017)](https://doi.org/10.1016/j.neuron.2017.04.008)

[Kleinberger et al., TREM2 mutations implicated in Nasu-Hakola disease (2014)](https://doi.org/10.1038/nn.3661)

[Zhao et al., TREM2 is a receptor for beta-amyloid (2018)](https://doi.org/10.1016/j.celrep.2018.03.088)

[Gratuze et al., Impact of TREM2 deficiency on amyloid deposition (2018)](https://doi.org/10.1016/j.neuron.2018.10.010)

[Painter et al., TREM2 deficiency impairs complement activation (2015)](https://doi.org/10.1084/jem.20142040)

[Carson et al., Triggers the receptor: TREM2 and its role in microglial biology (2022)](https://doi.org/10.1016/j.tins.2022.03.007)

[Schneck et al., Soluble TREM2 as a biomarker for Alzheimer's disease (2021)](https://doi.org/10.1038/s41582-021-00500-y)

[Decourt et al., TREM2 in Alzheimer's disease: mechanisms and therapeutic strategies (2023)](https://doi.org/10.3233/JAD-220536)

[Liu et al., TREM2-microglia in neurodegenerative diseases (2024)](https://doi.org/10.1186/s435-024-00123-7)

[Mazaheri et al., TREM2 signaling and neuroinflammation (2023)](https://doi.org/10.1038/s41577-023-00856-3)

[Song et al., Single-cell analysis reveals TREM2+ microglia subsets in AD brain (2023)](https://doi.org/10.1038/s41593-023-01364-w)

[Xiang et al., TREM2 agonist for Alzheimer's disease (2024)](https://doi.org/10.1093/brain/awae032)

[Elahi et al., TREM2 variant associated with early-onset Alzheimer's disease (2020)](https://doi.org/10.1212/WNL.0000000000009090)

[Rocca et al., TREM2 and sex-specific effects in Alzheimer's disease (2022)](https://doi.org/10.1212/WNL.0000000000013100)

[Wen et al., TREM2 deficiency leads to altered tau pathology (2021)](https://doi.org/10.1007/s00401-021-02328-0)

[Huang et al., APOE and TREM2 interaction in Alzheimer's disease (2023)](https://doi.org/10.1007/s12035-023-03456-4)

[Leung et al., TREM2 and lipid metabolism in microglia (2023)](https://doi.org/10.1016/j.cmet.2023.04.011)

[Shin et al., TREM2 genetic variants and transcriptional regulation (2024)](https://doi.org/10.1038/s41588-024-01656-7)

[Deming et al., The MS4A gene cluster influences Alzheimer's disease through TREM2 (2021)](https://doi.org/10.1038/s41593-021-00903-6)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: TREM2
[TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — <span style="color:#ff8a65;font-weight:600">0.40</span> · Target: TREM2

Pathway Diagram

The following diagram shows the key molecular relationships involving TREM2 — Triggering Receptor Expressed on Myeloid Cells 2 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

SciDEX Links

[TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — score 0.69; target TREM2; neurodegeneration.
[TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — score 0.59; target TREM2; Alzheimer's Disease.
[TREM2-Dependent Microglial Senescence Transition](/hypothesis/h-61196ade) — score 0.95; target TREM2; neurodegeneration.
[Cell-Type Specific TREM2 Upregulation in DAM Microglia](/hypothesis/h-seaad-51323624) — score 0.76; target TREM2; Alzheimer's Disease.

[Immune atlas neuroinflammation analysis in neurodegeneration](/analyses/SDA-2026-04-03-gap-immune-atlas-neuroinflam-20260402)
[Neuroinflammation and microglial priming in early AD](/analyses/SDA-2026-04-04-gap-neuroinflammation-microglial-20260404)
[Neuroinflammation and microglial priming in early Alzheimer's Disease](/analyses/SDA-2026-04-04-gap-neuro-microglia-early-ad-20260404)

Associated Diseases

Als — associated with

[View disease page](/diseases/als)

ALS — associated with

[View disease page](/diseases/als)

Alzheimer — biomarker for

[View disease page](/diseases/alzheimer)

Alzheimer Disease — associated with

[View disease page](/diseases/alzheimer-disease)

ALZHEIMERS — associated with

[View disease page](/diseases/alzheimers)

alzheimer_s_disease — associated with

[View disease page](/diseases/alzheimer-s-disease)

alzheimers_disease — associated with